Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies

NCT02666248 · clinicaltrials.gov ↗

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Subjects Entering Into This Protocol Will be Followed for up to 15 Years After Initial CART-EGFRvIII Infusion

Sponsor

University of Pennsylvania